177 related articles for article (PubMed ID: 35782609)
81. Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report.
Uşurelu N; Blăniţă D; Boiciuc C; Hlistun V; Egorov V; Popovici E; Gnatcova E; Stamati A; Oglindă A; Revenco N; Gladun S; Ţurea V
Med Pharm Rep; 2021 Aug; 94(Suppl No 1):S57-S60. PubMed ID: 34527913
[TBL] [Abstract][Full Text] [Related]
82. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.
Sawicka-Gutaj N; Machaczka M; Kulińska-Niedziela I; Bernardczyk-Meller J; Gutaj P; Sowiński J; Ruchała M
Ups J Med Sci; 2016 Aug; 121(3):192-5. PubMed ID: 27064303
[TBL] [Abstract][Full Text] [Related]
83. Long-term effectiveness of eliglustat treatment: A real-world analysis from the International Collaborative Gaucher Group Gaucher Registry.
Mistry PK; Balwani M; Charrow J; Lorber J; Niederau C; Carwile JL; Oliveira-Dos-Santos A; Perichon MG; Uslu Cil S; Kishnani PS
Am J Hematol; 2024 Apr; ():. PubMed ID: 38686876
[TBL] [Abstract][Full Text] [Related]
84. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
[TBL] [Abstract][Full Text] [Related]
85. A very rare cause of protein losing enteropathy: Gaucher disease.
Göktaş MA; Gümüş E; Demir H; Gülşen HH; Saltık-Temizel İN; Özen H; Güçer Ş; Yüce A
Turk J Pediatr; 2021; 63(4):708-715. PubMed ID: 34449155
[TBL] [Abstract][Full Text] [Related]
86. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
87. Once- versus twice-daily dosing of eliglustat in adults with Gaucher disease type 1: The Phase 3, randomized, double-blind EDGE trial.
Charrow J; Fraga C; Gu X; Ida H; Longo N; Lukina E; Nonino A; Gaemers SJM; Jouvin MH; Li J; Wu Y; Xue Y; Peterschmitt MJ
Mol Genet Metab; 2018 Mar; 123(3):347-356. PubMed ID: 29358012
[TBL] [Abstract][Full Text] [Related]
88. Clinical Characteristics, Molecular Background, and Survival of Egyptian Patients With Gaucher Disease Over a 20-Year Follow-up.
El-Beshlawy A; Abdel-Azim K; Abdel-Salam A; Gebril NA; Selim YMM; Said F
J Pediatr Hematol Oncol; 2022 Jul; 44(5):243-248. PubMed ID: 34310471
[TBL] [Abstract][Full Text] [Related]
89. Clinicogenetic Profile, Treatment Modalities, and Mortality Predictors of Gaucher Disease: A 15-Year Retrospective Study.
Barney AM; Danda S; Abraham A; Fouzia NA; Gowdra A; Abraham SSC; Sony M; Das S; Korula S; Mathai S; Simon A; Kumar S
Public Health Genomics; 2021; 24(3-4):139-148. PubMed ID: 33823526
[TBL] [Abstract][Full Text] [Related]
90. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
Reed MC; Bauernfreund Y; Cunningham N; Beaton B; Mehta AB; Hughes DA
Gene; 2018 Dec; 678():196-206. PubMed ID: 30099023
[TBL] [Abstract][Full Text] [Related]
91. Successful therapy for protein-losing enteropathy caused by chronic neuronopathic Gaucher disease.
Mhanni AA; Kozenko M; Hartley JN; Deneau M; El-Matary W; Rockman-Greenberg C
Mol Genet Metab Rep; 2016 Mar; 6():13-5. PubMed ID: 27014572
[TBL] [Abstract][Full Text] [Related]
92. Outcome of early-treated type III Gaucher disease patients.
Lee NC; Chien YH; Wong SL; Sheen JM; Tsai FJ; Peng SF; Leung JH; Chao MC; Shun CT; Hwu WL
Blood Cells Mol Dis; 2014 Sep; 53(3):105-9. PubMed ID: 24984925
[TBL] [Abstract][Full Text] [Related]
93. Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma.
Ramaswami U; Mengel E; Berrah A; AlSayed M; Broomfield A; Donald A; Seif El Dein HM; Freisens S; Hwu WL; Peterschmitt MJ; Yoo HW; Abdelwahab M
Mol Genet Metab; 2021 Aug; 133(4):335-344. PubMed ID: 34229967
[TBL] [Abstract][Full Text] [Related]
94. Modelling long-term evolution of chitotriosidase in non-neuronopathic Gaucher disease.
Drugan C; Drugan TC; Grigorescu-Sido P; Naşcu I
Scand J Clin Lab Invest; 2017 Jul; 77(4):275-282. PubMed ID: 28319420
[TBL] [Abstract][Full Text] [Related]
95. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
96. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
97. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.
Cox-Brinkman J; van Breemen MJ; van Maldegem BT; Bour L; Donker WE; Hollak CE; Wijburg FA; Aerts JM
J Inherit Metab Dis; 2008 Dec; 31(6):745-52. PubMed ID: 18850301
[TBL] [Abstract][Full Text] [Related]
98. Effectiveness and safety of the treatment of lysosomal deposit diseases: Analysis of 22 patients.
Canales-Siguero D; García-Muñoz C; Quijada Fraile P; Morales Conejo M; Ferrari-Piquero JM; Martín-Hernández E
Med Clin (Barc); 2022 Oct; 159(8):380-384. PubMed ID: 35688745
[TBL] [Abstract][Full Text] [Related]
99. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
100. Should eliglustat be first line therapy for patients with type 1 Gaucher disease? Definitions of safety and efficacy.
Zimran A; Goldblatt J; Szer J
Blood Cells Mol Dis; 2018 Feb; 68():14-16. PubMed ID: 28935503
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
